921 related articles for article (PubMed ID: 30659266)
1. The m
Cheng M; Sheng L; Gao Q; Xiong Q; Zhang H; Wu M; Liang Y; Zhu F; Zhang Y; Zhang X; Yuan Q; Li Y
Oncogene; 2019 May; 38(19):3667-3680. PubMed ID: 30659266
[TBL] [Abstract][Full Text] [Related]
2. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner.
Han J; Wang JZ; Yang X; Yu H; Zhou R; Lu HC; Yuan WB; Lu JC; Zhou ZJ; Lu Q; Wei JF; Yang H
Mol Cancer; 2019 Jun; 18(1):110. PubMed ID: 31228940
[TBL] [Abstract][Full Text] [Related]
3. METTL3/YTHDF2 m
Xie H; Li J; Ying Y; Yan H; Jin K; Ma X; He L; Xu X; Liu B; Wang X; Zheng X; Xie L
J Cell Mol Med; 2020 Apr; 24(7):4092-4104. PubMed ID: 32126149
[TBL] [Abstract][Full Text] [Related]
4. METTL3/YTHDF2 m6A axis promotes the malignant progression of bladder cancer by epigenetically suppressing RRAS.
Chen JX; Chen DM; Wang D; Xiao Y; Zhu S; Xu XL
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36960869
[TBL] [Abstract][Full Text] [Related]
5. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2.
Chen M; Wei L; Law CT; Tsang FH; Shen J; Cheng CL; Tsang LH; Ho DW; Chiu DK; Lee JM; Wong CC; Ng IO; Wong CM
Hepatology; 2018 Jun; 67(6):2254-2270. PubMed ID: 29171881
[TBL] [Abstract][Full Text] [Related]
6. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
7. The m
Gao Q; Zheng J; Ni Z; Sun P; Yang C; Cheng M; Wu M; Zhang X; Yuan L; Zhang Y; Li Y
Stem Cells Int; 2020; 2020():8849218. PubMed ID: 32676121
[TBL] [Abstract][Full Text] [Related]
8. METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer.
Yue B; Song C; Yang L; Cui R; Cheng X; Zhang Z; Zhao G
Mol Cancer; 2019 Oct; 18(1):142. PubMed ID: 31607270
[TBL] [Abstract][Full Text] [Related]
9. YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m
Chai RC; Chang YZ; Chang X; Pang B; An SY; Zhang KN; Chang YH; Jiang T; Wang YZ
J Hematol Oncol; 2021 Jul; 14(1):109. PubMed ID: 34246306
[TBL] [Abstract][Full Text] [Related]
10. METTL3/METTL14 Transactivation and m
Feng Y; Dong H; Sun B; Hu Y; Yang Y; Jia Y; Jia L; Zhong X; Zhao R
Cell Mol Gastroenterol Hepatol; 2021; 12(3):839-856. PubMed ID: 33992834
[TBL] [Abstract][Full Text] [Related]
11. HBXIP promotes gastric cancer
Yang Z; Jiang X; Li D; Jiang X
Aging (Albany NY); 2020 Oct; 12(24):24967-24982. PubMed ID: 33048840
[TBL] [Abstract][Full Text] [Related]
12. JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA.
Ni Z; Sun P; Zheng J; Wu M; Yang C; Cheng M; Yin M; Cui C; Wang G; Yuan L; Gao Q; Li Y
Cancer Res; 2022 May; 82(9):1789-1802. PubMed ID: 35502544
[TBL] [Abstract][Full Text] [Related]
13. METTL3 restrains papillary thyroid cancer progression via m
He J; Zhou M; Yin J; Wan J; Chu J; Jia J; Sheng J; Wang C; Yin H; He F
Mol Ther; 2021 May; 29(5):1821-1837. PubMed ID: 33484966
[TBL] [Abstract][Full Text] [Related]
14. METTL3 facilitates tumor progression via an m
Li T; Hu PS; Zuo Z; Lin JF; Li X; Wu QN; Chen ZH; Zeng ZL; Wang F; Zheng J; Chen D; Li B; Kang TB; Xie D; Lin D; Ju HQ; Xu RH
Mol Cancer; 2019 Jun; 18(1):112. PubMed ID: 31230592
[TBL] [Abstract][Full Text] [Related]
15. METTL3 enhances the stability of MALAT1 with the assistance of HuR via m6A modification and activates NF-κB to promote the malignant progression of IDH-wildtype glioma.
Chang YZ; Chai RC; Pang B; Chang X; An SY; Zhang KN; Jiang T; Wang YZ
Cancer Lett; 2021 Jul; 511():36-46. PubMed ID: 33933553
[TBL] [Abstract][Full Text] [Related]
16. N
Jin H; Ying X; Que B; Wang X; Chao Y; Zhang H; Yuan Z; Qi D; Lin S; Min W; Yang M; Ji W
EBioMedicine; 2019 Sep; 47():195-207. PubMed ID: 31409574
[TBL] [Abstract][Full Text] [Related]
17. METTL3-dependent N
Chien CS; Li JY; Chien Y; Wang ML; Yarmishyn AA; Tsai PH; Juan CC; Nguyen P; Cheng HM; Huo TI; Chiou SH; Chien S
Proc Natl Acad Sci U S A; 2021 Feb; 118(7):. PubMed ID: 33579825
[TBL] [Abstract][Full Text] [Related]
18. METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
Ai Y; Liu S; Luo H; Wu S; Wei H; Tang Z; Li X; Lv X; Zou C
J Immunol Res; 2021; 2021():6149558. PubMed ID: 34476262
[TBL] [Abstract][Full Text] [Related]
19. [Methyltransferase-like 3 Promotes the Proliferation of Acute Myeloid Leukemia Cells by Regulating N6-methyladenosine Levels of MYC].
Wang XS; He JR; Yu S; Yu J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Jun; 40(3):308-314. PubMed ID: 29978784
[TBL] [Abstract][Full Text] [Related]
20. Transcription factor RELA promotes hepatocellular carcinoma progression by promoting the transcription of m6A modulator METTL3.
Wu J; Wang W; Zheng Y; Deng W; Liu J
Pathol Res Pract; 2024 Mar; 255():155168. PubMed ID: 38367599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
